Sivan G. Marcus

Learn More
Drug discovery and development are hampered by high failure rates attributed to the reliance on non-human animal models employed during safety and efficacy testing. A fundamental problem in this inefficient process is that non-human animal models cannot adequately represent human biology. Thus, there is an urgent need for high-content in vitro systems that(More)
Human organ-on-a-chip systems for drug screening have evolved as feasible alternatives to animal models, which are unreliable, expensive, and at times erroneous. While chips featuring single organs can be of great use for both pharmaceutical testing and basic organ-level studies, the huge potential of the organ-on-a-chip technology is revealed by connecting(More)
Drug discovery and development to date has relied on animal models, which are useful but are often expensive, slow, and fail to mimic human physiology. The discovery of human induced pluripotent stem (iPS) cells has led to the emergence of a new paradigm of drug screening using human and disease-specific organ-like cultures in a dish. Although classical(More)
This hypothesis suggests that repeated viral infections disrupt the biosynthesis of P.G.E. 1 and nullify a major system by which t lymphocytes are regulated. It is hypothesized that a breakdown of P.G.E. 1 synthesis is responsible for the acquired immunodeficiency syndrome and the frequently associated Kaposi's sarcoma. A means of restoring P.G.E. 1(More)
  • 1